DBV Technologies Presents Its Strategy at the Biotech Summit
DBV Technologies announces the participation of its CEO at a major conference organized by Guggenheim Securities. This presentation is part of the biopharmaceutical company's institutional communication with investors and industry stakeholders.
Daniel Tassé, CEO of DBV Technologies, will speak on Thursday, February 12, 2026, at 2:30 PM Eastern Time during the Guggenheim Securities Emerging Outlook: Biotech Summit, which will be held in New York on February 11 and 12, 2026. His appearance will take the form of an informal discussion ('fireside chat'), a classic format for engaging with investors at specialized conferences.
Live Webcast and Recording Details
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
A live webcast of the 'fireside chat' will be available on the company's website in the Investors / Events section. A recording will remain accessible for 90 days following the event. DBV Technologies continues to specialize in the development of treatments for food allergies and immunological conditions, focusing its efforts on the use of its proprietary technology, the VIASKIN® patch, with ongoing clinical studies particularly in young children allergic to peanuts.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1M€dedollars
Net income: -47,6M€dedollars
Free cash flow: -49M€dedollars
Guidance from the release
Toute l'équipe de DBV démontre une focalisation et une rigueur exceptionnelles alors que nous abordons des étapes décisives au cours des prochains mois.
Risks mentioned
Augmentation significative des dépenses de R&D.
Perte nette en hausse à 47,6 millions de dollars.
Opportunities identified
Dépôt de la demande de licence biologique prévu pour 2026.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
